The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the

10 Most Volatile Penny Stocks to Buy Now.

On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an Early-Stage Biotech rating. Johnson said the company’s “differentiated approach” in metastatic breast cancer could unlock a $10B opportunity.

On May 12, 2026, Prelude Therapeutics Incorporated (NASDAQ:PRLD) reported Q1 EPS of (13c), compared to the consensus estimate of (27c). CEO Kris Vaddi said the company continued to show “focused execution” against the strategic priorities it set late last year. Vaddi cited the advancement of PRT12396 into first-in-human studies, preclinical data from its KAT6A degrader development candidate, progress toward a development candidate from its mCALR program, and a cash runway extended into the second quarter of 2028.

On May 4, 2026, D. Boral Capital initiated coverage of Prelude Therapeutics Incorporated (NASDAQ:PRLD) with a Buy rating and a $9 price target. D. Boral described Prelude as a clinical-stage oncology company advancing a precision medicine approach through a pipeline targeting epigenetic and DNA damage response pathways. The firm cited the company’s “deep pipeline,” emerging clinical validation, and multiple near-term catalysts, while also saying Prelude has validated its JAK2 franchise through a program-specific agreement with Incyte.

Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage precision oncology company focused on developing novel precision cancer medicines for underserved patients.

While we acknowledge the potential of PRLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.